Cargando…

Sarcopenia and Visceral Adiposity Did Not Affect Efficacy of Immune-Checkpoint Inhibitor Monotherapy for Pretreated Patients With Advanced Non-Small Cell Lung Cancer

BACKGROUND: This study aimed to investigate the association of computed tomography (CT)-assessed sarcopenia and visceral adiposity with efficacy and prognosis of immune-checkpoint inhibitor (ICI) therapy for pretreated non-small cell lung cancer (NSCLC). METHODS: We retrospectively collected 74 pati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Minami, Seigo, Ihara, Shouichi, Tanaka, Tsunehiro, Komuta, Kiyoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elmer Press 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011908/ https://www.ncbi.nlm.nih.gov/pubmed/32095185 http://dx.doi.org/10.14740/wjon1225

Ejemplares similares

Sarcopenia and Visceral Adiposity Are Not Independent Prognostic Markers for Extensive Disease of Small-Cell Lung Cancer: A Single-Centered Retrospective Cohort Study
por: Minami, Seigo, et al.
Publicado: (2020)

Pretreatment Lung Immune Prognostic Index Is a Prognostic Marker of Chemotherapy and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
por: Minami, Seigo, et al.
Publicado: (2019)

Pretreatment Lymphocyte to Monocyte Ratio as a Prognostic Marker for Advanced Pulmonary Squamous Cell Carcinoma Treated With Chemotherapy
por: Minami, Seigo, et al.
Publicado: (2018)

Gustave Roussy Immune Score and Royal Marsden Hospital Prognostic Score Are Biomarkers of Immune-Checkpoint Inhibitor for Non-Small Cell Lung Cancer
por: Minami, Seigo, et al.
Publicado: (2019)

Pretreatment Glasgow prognostic score and prognostic nutritional index predict overall survival of patients with advanced small cell lung cancer
por: Minami, Seigo, et al.
Publicado: (2017)

Gustave Roussy Immune Score Is a Prognostic Factor for Chemotherapy-Naive Pulmonary Adenocarcinoma With Wild-Type Epidermal Growth Factor Receptor
por: Minami, Seigo, et al.
Publicado: (2019)

Gustave Roussy Immune Score and Royal Marsden Hospital Prognostic Score Are Prognostic Markers for Extensive Disease of Small Cell Lung Cancer
por: Minami, Seigo, et al.
Publicado: (2020)

Low Body Mass Index Is an Independent Prognostic Factor in Patients With Non-Small Cell Lung Cancer Treated With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
por: Minami, Seigo, et al.
Publicado: (2019)

Secondary organizing pneumonia after coronavirus disease 2019: Two cases
por: Kanaoka, Kensuke, et al.
Publicado: (2021)

Neutrophil-to-Lymphocyte Ratio Predicts Overall Survival of Advanced Non-Small Cell Lung Cancer Harboring Mutant Epidermal Growth Factor Receptor
por: Minami, Seigo, et al.
Publicado: (2017)

Trajectory of chemotherapy for patients with EGFR wild-type advanced pulmonary adenocarcinoma: a single-institution retrospective study
por: Minami, Seigo, et al.
Publicado: (2017)

Retrospective analysis of outcomes and prognostic factors of chemotherapy for small-cell lung cancer
por: Minami, Seigo, et al.
Publicado: (2016)

Outcomes and prognostic factors of chemotherapy for patients with locally advanced or metastatic pulmonary squamous cell carcinoma
por: Minami, Seigo, et al.
Publicado: (2016)

Pulmonary Adenosquamous Cell Carcinoma With Systemic Lymphadenopathy due to Immunoglobulin G4-Related Disease: A Case Report
por: Ikebe, Saori, et al.
Publicado: (2021)

Lymphocyte to Monocyte Ratio and Modified Glasgow Prognostic Score Predict Prognosis of Lung Adenocarcinoma Without Driver Mutation
por: Minami, Seigo, et al.
Publicado: (2018)

Combination chemotherapy of gemcitabine and vinorelbine for pretreated non-small-cell lung cancer: a retrospective study
por: Minami, Seigo, et al.
Publicado: (2015)

High neutrophils and low lymphocytes percentages in bronchoalveolar lavage fluid are prognostic factors of higher in-hospital mortality in diffuse alveolar hemorrhage
por: Kanaoka, Kensuke, et al.
Publicado: (2021)

Successful Treatment of Allergic Bronchopulmonary Aspergillosis Using a Combination of Inhaled Fluticasone Furoate/Vilanterol and Oral Voriconazole
por: Nishimatsu, Kanako, et al.
Publicado: (2020)

Growth of Mediastinal Bronchial Artery Aneurysms in a Patient With Bronchiectasis
por: Noda, Yoshimi, et al.
Publicado: (2019)

Lambert-Eaton Myasthenic Syndrome Caused by Nivolumab in a Patient with Squamous Cell Lung Cancer
por: Nakatani, Yuki, et al.
Publicado: (2018)

Combination chemotherapy with intermittent erlotinib and pemetrexed for pretreated patients with advanced non-small cell lung cancer: a phase I dose-finding study
por: Minami, Seigo, et al.
Publicado: (2012)

Diffuse Alveolar Hemorrhage Induced by Irinotecan for a Patient with Metastatic Thymic Carcinoma: A Case Report and Literature Review
por: Kim, Sung-Ho, et al.
Publicado: (2017)

Durvalumab-Induced Diffuse Alveolar Hemorrhage: An Autopsy Case Report
por: Kanaoka, Kensuke, et al.
Publicado: (2020)

Influence of indacaterol on daily physical activity in patients with untreated chronic obstructive pulmonary disease
por: Nishijima, Yu, et al.
Publicado: (2015)

Association of obesity, visceral adiposity, and sarcopenia with an increased risk of metabolic syndrome: A retrospective study
por: Kim, Su Hwan, et al.
Publicado: (2021)

Effects of additive interactions among obesity, visceral adiposity, and sarcopenia on nonalcoholic fatty liver disease
por: Chung, Goh Eun, et al.
Publicado: (2023)

Liver metastasis affects progression pattern during immune checkpoint inhibitors monotherapy in gastric cancer
por: Motoo, Iori, et al.
Publicado: (2023)

Ambulatory pulse oximetry monitoring in Japanese COPD outpatients not receiving oxygen therapy
por: Minami, Seigo, et al.
Publicado: (2014)

Sarcopenia and Visceral Obesity are Significantly Related to Severe Storage Symptoms in Geriatric Female Patients
por: Hashimoto, Mamoru, et al.
Publicado: (2021)

Sarcopenia and visceral adiposity predict poor overall survival in hepatocellular carcinoma patients after curative hepatic resection
por: Jang, Hee Yoon, et al.
Publicado: (2021)

Model containing sarcopenia and visceral adiposity can better predict the prognosis of hepatocellular carcinoma: a multicenter study
por: Liu, Yao, et al.
Publicado: (2023)

Pretreatment Lung Function and Checkpoint Inhibitor Pneumonitis in NSCLC
por: Reuss, Joshua E., et al.
Publicado: (2021)

Opioid switch from low dose of oral oxycodone to transdermal fentanyl matrix patch for patients with stable thoracic malignancy-related pain
por: Minami, Seigo, et al.
Publicado: (2014)

Visceral adiposity syndrome
por: Lopes, Heno F., et al.
Publicado: (2016)

Association of mean corpuscular volume with sarcopenia and visceral obesity in individuals without anemia
por: Tanaka, Muhei, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: Monotherapies and Combined Therapies
por: Ouyang, Tao, et al.
Publicado: (2022)

Transformation From Adenocarcinoma to Pleomorphic Carcinoma as an Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
por: Nishimatsu, Kanako, et al.
Publicado: (2021)

Pretreatment nutritional status and response to checkpoint inhibitors in lung cancer
por: Lee, Chung-Shien, et al.
Publicado: (2020)

Efficacy and safety of immune checkpoint inhibitor monotherapy in elderly patients with non‐small cell lung cancer
por: Chikaishi, Yasuhiro, et al.
Publicado: (2021)

Subcutaneous adipose tissue & visceral adipose tissue
por: Mittal, Balraj
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_g96a7utreapd4jfo3upaq7eqcq